In Brief
Since chronic activation promotes terminal T cell differentiation (exhaustion), it has remained unclear how checkpoint blockade mediates a proliferative response of tumorinfiltrating T cells. Siddiqui et al. identify intratumoral, tumor-reactive Tcf1 + PD-1 + CD8 + T cells that display stem-like properties and that promote tumor control in response to vaccination and checkpoint blockade immunotherapy.
SUMMARY
Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8 + T lymphocytes (TILs). The origin of this response has remained elusive because chronic activation promotes terminal differentiation or exhaustion of tumor-specific T cells. Here we identified a subset of tumor-reactive TILs bearing hallmarks of exhausted cells and central memory cells, including expression of the checkpoint protein PD-1 and the transcription factor Tcf1. Tcf1 + T cells in the blood of melanoma patients and among TILs of primary melanomas. Thus, immune checkpoint blockade relies not on reversal of T cell exhaustion programs, but on the proliferation of a stem-like TIL subset.
INTRODUCTION
The extent of CD8 + T cell infiltration into certain tumors is predictive of overall patient survival, indicating that lymphocytes can restrict tumor outgrowth. Notwithstanding, most infiltrated tumors progress, suggesting that spontaneous anti-tumor immune responses are usually insufficient to control tumors. Immunotherapy aims at boosting anti-tumor immune responses to induce durable tumor control. Current approaches include adoptive cell therapy of autologous T cells and the blockade of inhibitory receptors (''immune checkpoints''), and these have yielded unprecedented clinical benefit in several tumor types (Rosenberg and Restifo, 2015; Ribas and Wolchok, 2018) . Clinical responses correlate with preexisting CD8 + T cell infiltration and the neoantigen burden (Tumeh et al., 2014; Schumacher and Schreiber, 2015) . Advances in cancer genomics and proteomics have revolutionized the discovery of such tumor neoantigens, which are usually unique to individual patients (Schumacher and Schreiber, 2015) . Personalized therapeutic vaccination against neoantigens may thus provide an additional approach for effective immune therapy. Indeed, therapeutic vaccination can be as effective as checkpoint blockade in preclinical mouse models (Gubin et al., 2014) . However, T cell responses to neoantigens as well as tumorassociated antigens are often compromised (Baitsch et al., 2011; Gros et al., 2014) , highlighting the urgency of better understanding the mechanisms whereby therapeutic vaccination or checkpoint blockade improves the T cell response to tumors. Persistent exposure to cognate antigen due to progressively growing tumors or chronic viral infection promotes an epigenetic T cell differentiation program that severely limits effector functions, alters the metabolic fitness, and induces negative regulators of T cell function such as the co-inhibitory receptor PD-1 (programmed cell death protein 1) (Wherry and Kurachi, 2015) . This exhausted phenotype is generally thought to describe terminally differentiated cells that have lost expansion capacity and may be short-lived. However, the notion of terminal differentiation is difficult to reconcile with the proliferation of intratumoral CD8 + T cells in response to PD-1 blockade (Tumeh et al., 2014) . In addition, tumor-derived T cells expanded in vitro can mediate therapeutic responses after adoptive transfer (Rosenberg and Restifo, 2015) , indicating that tumor-reactive T cells are not completely differentiated or that a subset of these cells is less differentiated (Speiser et al., 2014) .
Tumor-infiltrating CD8 + T cells show significant heterogeneity both in cancer patients and experimental models (Reiser and Banerjee, 2016; Tirosh et al., 2016; Singer et al., 2016; Wei et al., 2017) . However, the functional relevance of the different subsets described is unclear as the specificity of intratumoral CD8 + T cells was not defined, and moreover, a considerable fraction of infiltrating CD8 + T cells are bystanders (Simoni et al., 2018) . Further, the diversity of CD8 + T cells may originate from cells initially present in the blood or other tissues or may derive from turnover within the tumor. Consequently, the source and the clonal relationship of intratumoral CD8 + T cell subsets remains poorly understood.
Similar to tumors, chronic viral infections promote T cell exhaustion. Although exhaustion was thought to preclude the formation of T cell memory, the identification of a subset of virus-specific CD8 + T cells co-expressing the inhibitory PD-1 receptor and the transcription factor T cell factor 1 (Tcf1, encoded by Tcf7) that sustain the immune response in chronic infection presented a link between T cell memory and exhaustion (Utzschneider et al., 2016; Im et al., 2016; Wu et al., 2016) . Tcf1 is essential for the formation and function central memory CD8 + T cells after resolution of acute infections (Jeannet et al., 2010; Zhou et al., 2010) . Similarly, Tcf1 Figure S1 .
sion, which overlaps considerably with that of Tcf1 (Im et al., 2016) . Cxcr5 + CD8 + T cells reside in secondary lymphoid tissues of chronically infected mice, predominantly in the T cell zone (Im et al., 2016) . Here we addressed whether-similar to the immune response in chronic viral infection-spontaneous or immunotherapydriven anti-tumor CD8 + T cell responses involved a memory CD8 + T cell component and, if so, whether these cells were part of the tumor microenvironment. We found tumor-specific Tcf1 + PD-1 + CD8 + T cells that reside in the tumor microenvironment and that are critical for immune control of cancer promoted by immunotherapy.
RESULTS

Lack of Tcf1 in Tumor-Reactive CD8 + T Cells Diminishes
Tumor Control in Response to Therapeutic Vaccination To address whether CD8 + T cell responses to tumors or the beneficial effects of immunotherapy involved a memory component, we tested whether such responses depended on the transcription factor Tcf1, which is essential for the formation and function of central memory CD8 + T cells (Jeannet et al., 2010; Zhou et al., 2010) . Wild-type or Tcf7 À/À CD8 + T cells specific for the surrogate tumor antigen LCMV gp33 (P14) (CD45.2) were adoptively transferred into naive C57BL/6 (B6) mice (CD45.1). One day later, such P14 chimeric mice were implanted subcutaneously (s.c.) with B16 melanoma cells expressing LCMV gp33 (B16-gp33) ( Figure 1A ). This approach was used to follow tumor-specific CD8 + T cells and to determine whether these cells or subsets thereof were relevant for tumor control. Figures 1B and 1C ). This correlated with a 10-fold higher abundance of WT as compared to Tcf7 À/À P14 tumor-infiltrating CD8 + T lymphocytes (TILs) at endpoint ( Figure 1D ). Tcf7 À/À P14 T cells were also less abundant (3-fold) in the tumor draining lymph node (dLN), while there was no difference in the spleen ( Figure S1C ). When TILs were analyzed approximately 1 week after vaccination (intermediate time point), WT and Tcf7 À/À P14 TILs were equally abundant ( Figure 1E ). Thus, P14 TILs lacking Tcf7 were abundant early after vaccination but declined thereafter and this correlated with reduced tumor control. Since extended tumor control depended on Tcf1, we characterized Tcf1 expression in WT P14 cells in both vaccinated and nontreated mice ( Figure 1A ). Naive P14 cells were homogenously Tcf1 + (see e.g., Figure 3A ). Similarly, most P14 TILs in palpable tumors (<100 mm 3 ) of untreated mice were Tcf1 + but also expressed PD-1 (Figure 2A ), indicating that they had been exposed to antigen. PD-1 + TILs and appeared more differentiated based on the frequent co-expression of GzmB. Corresponding results were obtained when Tcf1 expression was followed using a Tcf7 reporter, in which green fluorescent protein (GFP) had been introduced into a bacterial artificial chromosome (BAC) containing the Tcf7 locus (Tcf7 GFP ) (Utzschneider et al., 2016 ) (see later). To assess whether the isolated CD8 + T cells derived from the tumor, we performed in vivo vascular cell labeling. Unlike blood-borne P14 cells, which were homogenously stained with the i.v. injected fluorescent CD8a Ab, the vast majority (95%) of Tcf7 GFP+ and Tcf7 GFPÀ P14 cells isolated from tumors were not labeled ( Figure S2B ), which indicated that both subsets resided in the tumor. Thus Tcf1 + PD-1 + TILs were constitutively present in the tumor, their abundance transiently increased as tumors progressed, and these cells could be expanded further by therapeutic vaccination. The Tcf1 + PD-1 + P14 cells were also present in the tumordraining lymph node (dLN) ( Figure S2C ) and spleen of vaccinated mice (not shown). While P14 cells expressing Tcf1 and PD-1 were observed in the tumor of non-vaccinated mice in dLN (Figure S2C) or spleen (not shown), P14 cells did not express PD-1, indicating that these cells were not persistently exposed to antigen. Notwithstanding, peripheral P14 cells were CD44 + implying that they were antigen experienced. Vaccination thus amplified tumor-specific CD8 + TILs but was not critical to establish the observed TIL subset distribution (Figures 2A, 2B, and S2B) . This conclusion was supported by the presence of the corresponding TIL subsets among host CD8 + T cells ( Figure 2A ). Analogous results were obtained using a different melanoma cell line (YUMM-OVA) recognized by distinct tumor-specific CD8 + T cells (OT-I) ( Figure S2D ), using a thymoma cell line (E.G7-gp33) ( Figure S2E ) and during adoptive T cell therapy experiments ( Figure S2F Figure 2G ). Corresponding localizations were observed in non-vaccinated mice ( Figure S3D ). In vaccinated mice, Tcf7
GFP+ cells were part of T cell-rich, but B cell-poor, perivascular infiltrates of hematopoietic cells. These infiltrates did not contain segregated T cell and B cell zones ( Figure S3E ) and thus lacked the hallmarks of tertiary lymphoid structures (TLSs). Tcf7 GFP+ cells remained in relative proximity to tumor cells, as judged by their localization close to GFP-expressing B16-gp33 cells ( Figure S3F) Figure S4A ). GFP fluorescence was detected in essentially all CD8 + T cells, but not in B cells from naive Tcf7 DTR-GFP P14 mice, in agreement with Tcf1 protein expression ( Figure 3A ). Next, we generated Tcf7 DTR-GFP P14 chimeric mice and implanted them with B16-gp33 tumor cells. Mice were vaccinated when tumors became palpable and TILs were analyzed 6 days later ( Figure 3B Figure 3C ). Identical results were obtained in splenic Tcf7 DTR-GFP P14 cells ( Figure S4B ) and using the original Tcf7 GFP reporter ( Figure S4C ). These experiments ensured that GFP expression identified CD8 + TILs retaining high Tcf1 expression.
Short-term diphtheria toxin (DT) treatment efficiently deleted GFP + P14 TILs but had no effect on the abundance of GFP À P14 TILs ( Figure S4D ), demonstrating that DT treatment was effective and had no direct effect on Tcf1 À P14 TILs.
Tumor-bearing mice were thus treated with DT, revaccinated to boost the response, and analyzed 16 days later ( Figure 3B ). DT exposure resulted in a near complete absence of P14 cells expressing GFP ( Figure S4E ) or Tcf1 protein from TILs (Figure 3D) , the dLN ( Figure S4F ), or the spleen (not shown) of Tcf7 DTR-GFP P14 chimeric mice. Elimination of Tcf1 + P14 cells reduced the abundance of Tcf1 À P14 cells present among TILs (2.5-fold) ( Figures 3E and 3F ), the dLN ( Figure S4F ), or the spleen (5-to 6-fold) (not shown). This was not due to DT toxicity since P14 cells were abundant in DT-treated Tcf7 GFP P14 chimeric mice ( Figures 3E, 3F , S4E, and S4F). Thus, Tcf1 + cells sustained the production of Tcf1 À TILs.
The tumor volume ( Figure 3G ) and tumor weight ( Figure 3H ) upon sacrifice was low in Tcf7 DTR-GFP P14 chimeric mice. In contrast, tumors progressed when Tcf1 + P14 cells had been ablated. This was not due to DT toxicity, as tumors were controlled in DT-treated Tcf7 GFP P14 chimeric control mice (Figures 3G and 3H + T cells to the treatment response. We used the sphingosine 1-phosphate receptor-1 (S1PR1) inhibitor FTY720 to prevent the exit of T cells from lymphoid organs and thus to block the influx of new T cells into the tumor ( Figure 4A ; Mandala et al., 2002) . Just prior to FTY720 and DT treatment, all P14 TILs expressed PD-1 and a subset of around 15% was Tcf7 DTR-GFP+ ( Figure 4B ).
At the time of sacrifice, the abundance of circulating CD3 + T cells was reduced >90% in FTY720-treated animals (Figure 4C) , showing that T cell exit from lymphoid organs was blocked similar to published data (Spranger et al., 2014) . As above, DT treatment resulted in the complete absence of GFP + (not shown) or Tcf1 + P14 TILs in Tcf7 DTR-GFP P14 chimeric mice ( Figure 4D ). Preventing the influx of new lymphocytes did not impact the abundance of P14 TILs ( Figure 4F ). However, when lymphocyte immigration was blocked and Tcf1 + P14 TILs were depleted (initially around 15% of P14 TILs) ( Figure 4B ), the abundance of Tcf1 À P14 TILs was reduced 6-to 7-fold ( Figure 4F ). Thus in the absence of Tcf1 + PD-1 + TILs, the differentiated Tcf1 À PD-1 + GzmB + compartment was greatly Co-inhibitory receptors such as PD-1 and CTLA-4 (cytotoxic T lymphocyte antigen 4) restrain T cell antitumor immunity and their blockade mediates T cell-dependent tumor regression in preclinical animal models and cancer patients (Page et al., 2014) . However, the cellular basis for the efficacy of this therapeutic intervention has remained unclear. Our own experiments showed that such checkpoint blockade immunotherapy (CBI) expanded P14 TILs in a Tcf1-dependent fashion and that the combination of CBI with the adoptive transfer of Tcf1-sufficient P14 cells mediated efficient tumor control ( Figure S5 ). These findings raised the possibility that Tcf1 + CD8 + T cells played a role for tumor control in response to CBI. Since intratumoral cells controlled tumors in response to vaccination (see above) or CBI (Spranger et al., 2014) , we directly addressed whether intratumoral Tcf1 + cells were required for tumor control in response to CBI ( Figure 5A ).
We enrolled Tcf7 DTR-GFP P14 chimeric mice in CBI trials when B16-gp33 tumors were around 100 mm 3 . At this stage, all P14 TILs expressed PD-1 and around 15% were Tcf7 DTR-GFP+ (Fig- ure 5B). Influx of new T cells into the tumor was prevented using FTY720, Tcf1 + P14 TILs were ablated using DT, and CBI was initiated as schematically shown in Figure 5A .
Upon sacrifice, we confirmed FTY720-mediated depletion of CD3 + cells from blood (>90%) and efficient DT-mediated deletion of GFP + P14 cells from TILs. As compared to isotype con- (Table S1 ). ''Cytokine-cytokine receptor interaction'' represented the KEGG pathway term most significantly associated with increased (p = 1.45eÀ8) and with decreased (p = 3.8eÀ8) gene expression. TIL subsets were next compared to CD8 + T cells from chronic and acute resolved LCMV infections (Utzschneider et al., 2016) . The PC1 versus PC2 separated tumor-and infection-derived CD8 + T cell populations ( Figure S6A Figure 6B ). In agreement with these data, Tcf7 GFP+ TILs and memory-like cells expressed unique genes but also shared a considerable number of genes (n = 443, FDR < 5%, FC > 2) ( Figure S4B , Table S2 ), including Ly108 (Slamf6) and Cxcr5 ( Figures 6D and S6C) . Thus, despite their distinct biological context and tissue origin, the gene signatures of Tcf7 GFP+ TILs and chronic infection-derived cells significantly overlapped (A) B16-gp33 cells were implanted into Tcf7 DTR-GFP P14 chimeric mice, vaccinated when tumors became palpable, and analyzed 6 days later. Mice were then treated with FTY720 (FTY) to prevent de novo T cell immigration into the tumor, Tcf7 DTR-GFP+ P14 cells were ablated using DT and mice were revaccinated.
(B) Validation 6 days after vaccination: GFP expression by gated Tcf7 DTR-GFP P14 (left) as compared to host CD8 + TILs (middle) and PD-1 expression in Tcf7 DTR-GFP+ (green) and Tcf7 DTR-GFPÀ (blue) P14 TILs as compared to host CD8 + TILs (grey fill) (right). (legend continued on next page) ( Figure 6C ). The KEGG pathway terms ''cytokine-cytokine receptor interaction'' and ''natural killer cell-mediated cytotoxicity'' were most significantly associated with shared increased (p = 3.3eÀ10) and decreased (p = 2.53eÀ5) gene expression, respectively. The transcriptome of Tcf7 GFP+ TILs showed significant enrichment of a memory precursor (MPEC) gene set ( Figure 6C ; Joshi et al., 2007) and highly expressed several central memory markers (Tcf7, Sell [CD62L], Ccr7, Id3, Bcl6) ( Figures 6D and  S6D ). On the other hand, the transcriptome of Tcf7 GFP+ TILs was distinct from skin-derived tissue resident memory (Trm) cells (Figures 6C and S6E ; Mackay et al., 2013 Mackay et al., , 2016 . Indeed, Tcf7 GFP+ TILs inefficiently expressed several key genes associated with Trm cells including Prdm1 (Blimp1), Zfp613 (Hobit), and Runx3 ( Figure S6F ). Rather, the Trm cell signature was significantly enriched in Tcf7 GFPÀ TILs (Figures 6C and S6E) and the expression of certain Trm cell genes was increased in Tcf7 GFPÀ as compared to Tcf7 GFP+ TILs ( Figure S6F ). These data suggested that Tcf1 + PD-1 + TILs lacked Trm cell features but that they produced intratumoral progeny with Trm cell characteristics. Functionally, Tcf7 GFP+ TILs produced IL-2 both spontaneously and after restimulation ( Figure 6E ), a considerable fraction of these cells cycled based on KI67 expression and DNA content analysis ( Figure S6G ), and these cells were less prone to undergo apoptosis as compared to Tcf7 GFPÀ TILs (Figure S6H) . To assess the expansion potential of these cells, we transferred flow-sorted P14 TILs (CD45.2) into naive secondary recipients (CD45.1) followed by LCMV infection. While transferred Tcf7 GFPÀ P14 TILs essentially failed to expand,
Tcf7
GFP+ P14 TILs expanded significantly ( Figure 6F ). Progeny of Tcf7 GFP+ P14 TILs were predominantly Tcf7 GFPÀ although a subpopulation of Tcf7 GFP+ cells was also present and these cells had expanded as compared to input ( Figure 6G ). Thus, transferred Tcf7 GFP+ TILs had the potential to expand, differentiate, and reproduce Tcf7 GFP+ cells, which was consistent with the conclusions based on the in vivo ablation of Tcf1 + P14 TILs (Figure 4 ). In agreement with these stem cell-like properties, transcripts overrepresented in Tcf7 GFP+ P14 TILs significantly overlapped with a subset of genes expressed by adult stem cells (Wong et al., 2008) or by hematopoietic stem/progenitor cells but not by mature hematopoietic cells ( Figure S7A ; Ivanova et al., 2002) . Conversely, the transcriptome of short-lived effector cells (SLECs) (Joshi et al., 2007) was not enriched in Tcf7 GFP+ TILs ( Figure 6C ) and selected genes or proteins involved in effector T cell differentiation or function were present at low abundance in Tcf7 GFP+ TILs ( Figures 6H, S7B , and S7C). Further, Tcf7
GFP+
TILs produced less IFN-g but the same amount of TNF-a (not shown) as compared to Tcf7 GFPÀ TILs ( Figure 6E ). Finally, Tcf1 + TILs expressed less T-bet but more Eomes as compared to Tcf1 À TILs ( Figure S7C ), similar to observations in chronic viral infection (Utzschneider et al., 2016; Im et al., 2016) .
Despite the relative lack of an effector program, Tcf7 GFP+ TILs expressed multiple exhaustion markers (Lag3, Pdcd1, CTLA4) albeit usually at slightly lower amounts than Tcf7 GFPÀ TILs (Figures 6I, S7D , and S7E). Additional exhaustion-associated genes were more selectively expressed by Tcf7 GFPÀ TILs (Maf, Cd244
[2B4], Havcr2 [Tim3], Ccl3) ( Figures S7D and S7E ), indicating that increased expression of these genes was associated with differentiation. Finally, the transcriptome of Tcf7 GFP+ TILs was significantly enriched with the signature of follicular helper (Tfh) T cells (Figure 6C ) similar to memory-like cells (not shown) (Im et al., 2016 Figure S8B ). One week later, we observed a comparable abundance of WT and Tcf7 À/À P14 TILs ( Figure S8C ), consistent with Figure 1E . The abundance of Tcf7 GFP+ TILs was also comparable ( Figure S8C) Figure S8D ). Thus, Tcf1 protein was essential to maintain the Tcf7 GFP+ TIL population in response to restimulation. To begin to address the gene expression program(s) controlled by Tcf1, we combined our RNA-seq analyses with Tcf1 ChIP-seq data from naive CD8 + T cells (Xing et al., 2016) . Considering Tcf1 binding peaks within ±5 kb of genomic sequence flanking a gene, naive CD8 + T cells had 5,220 Tcf1-bound genes. Among 260 genes with increased expression in Tcf7 GFP+ TILs, 71 (27.3%) were bound by Tcf1, while 73 of the 309 decreased genes (23.6%) were bound by Tcf1 in naive CD8 + T cells (Table S1 ). While there was no specific KEGG term associated with these genes, we noted several effector genes among Tcf1-bound repressed genes (e.g., Granzymes, Id2, Klrg1). Thus, Tcf1 may maintain Tcf7 GFP+ TILs at least in part by counteracting cellular differentiation. Figure 7B ). These cells essentially lacked IL7Ra and were bimodal for CD45RA (Figure S9B) . Thus, similar to anti-tumor immune responses in mice, the blood of melanoma patients harbored tumor-specific TCF1 + PD-1 + CD8 + T cells as well as TCF1 Figures  S9D-S9F) . Clearly, however, TCF1 + PD-1 + CD8 + T cells were observed in the absence of TLSs, similar to murine tumors ( Figure S3E ).
To further characterize TCF1 + PD-1 + CD8 + TILs, we reanalyzed publicly available single-cell RNA-seq data of human melanomainfiltrating CD8 + T cells (Tirosh et al., 2016) . These analyses identified subpopulations of CD8A + TILs that co-expressed TCF7 and PDCD1 (PD-1) in two subjects ( Figures 7H and S9G . For each set, the number of genes (n), Data in (D), (E), (H), and (I) are representative of at least 2 analyses with n = 5 mice per group. Data in (F) and (G) are from a single experiment using Vb5 recipients, 2 additional experiments yielding comparable differences were performed using WT recipients, each experiment with n = 5 mice per group. All error bars are SD. Fridman et al. (2012) . We thus focused on melanomas with high T cell genes. Among these patients, TCF7 or PDCD1 expression did not have prognostic value. However, the combined expression of TCF7 and PDCD1 had significant power to predict overall improved patient survival ( Figure S9J ). Thus, meta-analysis of the TCGA database indicates that a TCF7/PDCD1 signature correlates with improved patient survival.
DISCUSSION
We found that intratumoral (Utzschneider et al., 2016; Im et al., 2016) . Such experiments address the developmental potential of these cells but not necessarily their physiological role. Here we established an in vivo cell ablation approach and confirmed the stem-like properties of Tcf1 neider et al., 2016; Im et al., 2016) . This is remarkable given the very different biological contexts and tissue origins of these cells and it is tempting to speculate that corresponding cells may exist in additional situations of chronic antigen stimulation. Notwithstanding, we also noted differences between the two types of CD8 + T cells. CXCR5 + memory-like CD8 + T cells in chronically infected mice are restricted to secondary lymphoid tissues (Im et al., 2016) . In contrast, Tcf1 + PD-1 + CD8 + T cells persisted and functioned outside secondary lymphoid organs, in tumor tissues. While these cells were present in occasional TLSs of human melanomas, they were also detected independent of TLSs, in both human and murine tumors. In the latter instance, specific perivascular niches may ensure the persistence of memory-like CD8 + T cells in tumors. Naive tumor-specific T cells are thought to expand and differentiate in the tumor draining lymph node and differentiated T cells home to the tumor (Chen and Mellman, 2017) . Our data raise the possibility that tumors are also infiltrated by activated but relatively undifferentiated tumor-reactive Tcf1 + CD8 + T cells, where they can persist and sustain the tumor immune response. There is indeed growing evidence that the tumor microenvironment supports T cell-mediated tumor immune responses. For example, intratumoral T cells proliferate during spontaneous tumor immune responses in mice (Horton et al., 2018) and in response to checkpoint blockade in melanoma patients (Tumeh et al., 2014) . Mouse models suggest that the proliferative response to PD-1 blockade depends on CD28-mediated co-stimulation (Kamphorst et al., 2017) and such data are in line with a role for intratumoral CD103 + dendritic cells (DCs) to re-stimulate and expand tumor-specific CD8 + T cells (Broz et al., 2014) . Finally, the local immune response has protective potential, as transferred tumor-specific CD8 + T cells (as shown herein) or endogenous TILs (Spranger et al., 2014) prevented tumor progression in response to checkpoint blockade even when the influx of new T cells was prevented.
Checkpoint blockade mediates a proliferative response of TILs, but the cellular and molecular basis for this response has remained obscure since tumor-reactive CD8 + T cells have an exhausted phenotype (Baitsch et al., 2011; Gros et al., 2014) . Either See also Figure S9 .
checkpoint blockade de-differentiated terminally differentiated T cells or it acted on less differentiated T cells that then produced an expanded pool of differentiated T cells. Our findings provide strong support for the latter scenario and suggest that expansion and differentiation can occur in the tumor. Indeed, ablation of intratumoral Tcf1 + PD-1 + cells revealed that Tcf1
lacked expansion capacity and that the residual cells were not sufficient to maintain tumor control. In addition to TIL expansion, blockade of inhibitory receptors also improves T cell effector functions including cytokine production and cytotoxicity. We expect that the improved effector functions predominantly stem from the de-inhibition of differentiated Tcf1 À PD-1 + TILs. If so, Tcf1
À PD-1 + TILs may be more directly responsible for tumor control. However, they may only do so effectively when de-inhibited and when produced in sufficient numbers from Tcf1 + precursors. The differentiation of TILs was associated with the loss of Tcf1 expression, raising the question regarding the relevant signals and the causal relationship. Using dendritic cell vaccinations, we have recently shown that inflammatory signals silence Tcf1 in activated T cells and that this facilitated effector differentiation (Danilo et al., 2018) . Similarly, inflammatory cues may suppress Tcf1 in the tumor to facilitate differentiation. Indeed, Tcf1-bound suppressed target genes include several effector genes. While inhibitory receptor blockade has revolutionized cancer care, this intervention is still effective only in a minority of cancer patients. Thus there is a considerable interest to predict which patients will benefit. Clinical responses correlate with preexisting CD8 + T cell infiltration and the neoantigen burden (Tumeh et al., 2014; Schumacher and Schreiber, 2015) . Our data suggest that clinical responses further depend on the presence of memorylike CD8 + T cells. Our preliminary analysis of a small cohort of pretreatment melanoma samples indicated that both responder and non-responder patients do have TCF1 + PD-1 + TILs. While larger cohorts will be needed to determine whether the abundance of these cells differs between responders and non-responders, their presence in non-responders does not contradict the findings reported herein. The preclinical mouse models showed that Tcf1 + PD-1 + cells are necessary for treatment response, but these cells are not likely sufficient. Recently, Sade-Feldman et al. (2018) reported the transcriptomes of a large number of individual CD8 + T cells derived from 48 human melanoma samples. The authors defined two distinct states of CD8 + T cells that were associated with tumor regression or progression whereby TCF7 expression was found to predict positive clinical outcome in checkpoint-treated patients. Intriguingly, the majority of TCF1 + CD8 + TILs usually lacks PD-1 expression and may not recognize the tumor. It thus remains to be determined whether or not the positive correlation noted above is based on TCF1 + CD8 + TILs that co-express PD-1. In addition to melanoma, CD8
+ TILs displaying memory-like features have been recently identified in lung cancer patients based on low PD-1 expression (Thommen et al., 2018) or the expression of CXCR5 (Brummelman et al., 2018) . Although the precise overlap between the distinct populations remains to be determined, memory-like CD8 + T cells seem to be present in several types of human tumors. Our investigations reveal a critical role of intratumoral CD8 + T cells co-expressing Tcf1 and PD-1 in immunotherapy-driven tumor control. The findings provide a basis for understanding how immune interventions impact immune responses against tumors. For example, the data suggest that checkpoint blockade or vaccination does not rejuvenate differentiated cells but rather acts on less-differentiated memory-like CD8 + T cells that produce an expanded pool of effector-type CD8 + T cells. The identification of these stem-like cells will likely help to further improve all types of cancer immunotherapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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STAR+METHODS EXPERIMENTAL MODEL AND SUBJECT DEAILS
Mouse strains were maintained in the SPF animal facility of the University of Lausanne. Tumor experiments used both male and female mice between 6 and 12 weeks of age. Donors and recipients of adoptive T cell transfers were sex matched. Groups of mice enrolled into treatment/control arms of immunotherapy trials were selected to have on average the same tumor volume. Animal experiments were conducted in accordance with protocols approved by the veterinary authorities of the Canton de Vaud.
Human blood specimens were collected in the framework of the previously reported Phase I clinical study protocol LUD 2000-018 (ClinicalTrials.gov Identifier: NCT00112229) approved by the Human Research Ethics Committee of Canton of Vaud of Lausanne University Hospital (CHUV), and the Departmental Ethics Committee of Medicine of Geneva University Hospital. Prior to the initiation of the work, the study protocol and amendments were also approved by the Swiss Regulatory Authority Swissmedic.
Human melanoma tissue specimens were diagnostic specimens of melanoma patients followed at CHUV, used for research purposes according to the protocol 2017-000174 approved by the Human Research Ethics Committee of the Canton of Vaud. (Utrecht, the Netherlands). Vb5 TCRb only transgenic mice were provided by P. Fink (Seattle, USA). Tcf7 GFP reporter mice have been described (Utzschneider et al., 2016) . Tcf7 DTR-GFP mice were generated using a bacterial artificial chromosome (BAC) containing the entire Tcf7 locus plus > 60kb of up and down stream sequence (RP23-223A11). A DTR-T2A-GFP polyA fusion gene was inserted into the endogenous translation start codon present in exon Ia' of Tcf7, which prevents Tcf1 expression from the BAC. Transgenic mice were generated by pronuclear injection into fertilized B6 oocytes (Cyagen Inc). Founder mice were identified by PCR and initially characterized by flow cytometry for GFP expression. P14 Tcf7
GFP , P14 Tcf7 À/À Tcf7 GFP and P14 Tcf7 DTR-GFP mice were obtained by breeding (all CD45.2 + ).
Cell lines, cell culture, plasmids and transduction B16.F10 melanoma cells expressing the LCMV glycoprotein epitope amino acid 33-41 (B16-gp33) (Pré vost-Blondel et al., 1998) were obtained from G. Verdeil (UNIL). B16-gp33 cells were infected with a pgk promoter EGFP Lentivirus to generate B16-gp33-GFP cells. E.G7 cells (derived from EL-4 thymoma) were transduced with a Lentivirus coding for a GFP-ubi-gp33 fusion construct kindly provided by F. Lé vy (LICR). A B-raf V600E/+ Pten À/À Cdkn2a À/À melanoma cell line (YUMM1.7) expressing Ovalbumin (YUMM-OVA) was kindly provided by P.-C. Ho (UNIL).
Ectopic tumor implantation and tumor volume and weight measurements
The right flank of mice was shaved and B16-gp33 cells (2.5x10 5 ), E.G7-gp33 cells (10 6 ) or YUMM-OVA cells (2x10 5 ) were injected subcutaneously (s.c.). Tumor volumes were estimated by measuring the tumor size in two dimensions using a caliper. The tumor volume was calculated according to the formula (length x width 2 )/2. Mice were sacrificed at the indicated time points or when the estimated tumor volume reached > 1cm 3 (endpoint) and the weight of the excised tumor mass was determined.
Adoptive T cell therapy B6 mice (CD45.1), implanted with B16-gp33 tumor cells, were sublethally irradited (5Gy) when tumors reached a size of around 150mm 3 . One day later mice were grafted with 3x10 5 P14 cells that had been activated in vitro i.e., CD8 + T cells purified from P14 mice activated in vitro with Ab to CD3 and CD28 plus IL2 (50ng/mL) for 3 days. CD8 + TIL were analyzed 10-12 days later.
Tumor digestion and preparation of single cell suspensions For TIL isolation, tumors were excised, manually dissociated and digested enzymatically with Tumor Dissociation Kit (Miltenyi Biotec). Digested tumors were mashed through 70 mm filters. Hematopoietic cells were further purified using a discontinuous Percoll gradient (GE Healthcare). Cells at the interface were harvested and washed twice before further use. Suspensions of spleen and lymph node cells were obtained by mashing the spleen or lymph node through a 100 mm nylon cell strainer (BD Falcon).
Adoptive T cell transfer, vaccination, antibody treatment, diphtheria toxin (DT) and FTY720 treatment P14 or OT-I CD8 + T cells from the indicated strains of mice were obtained by mashing the spleen through a 100 mm nylon cell strainer (BD Falcon). Red blood cells were lysed with a hypotonic Ammonium-Chloride-Potassium (ACK) buffer. CD8 + T cells were purified using mouse CD8 + T cell enrichment kit (StemCell Technologies). One million purified P14 (CD45.2) or OT-I T cells (CD45.2) (usually > 95% pure) was adoptively transferred i.v. into naive B6 mice (CD45.1 or CD45.2) one day prior to tumor cell implantation.
For vaccination, mice were injected s.c. with 50 mg poly(I:C) (Invivogen) together with antigenic peptides (LCMV glycoprotein amino acids 33-41 (gp33) (10 mg), or Ovalbumin amino acids 257-264 (OVA) (10 mg) or a mixture of gp33, melanoma antigen gp100 amino acids 209-217 (gp100) and tyrosinase-related protein 2 amino acids 180-188 (Trp2) (10 mg each) (TCMetrix)).
For checkpoint blockade, mice were injected i.p. with rat anti-mouse PD-1 (RMP1-14) (d0, d5 d10) (200 mg per injection) alternating with rat anti-mouse CTLA-4 (9D9) (d2, d7, d12) (200 mg per injection). As a control, mice were injected with rat IgG2b isotype control (LTF-2) (d0, d5, d10)(200 mg per injection).
For the depletion of DTR expressing cells, Diphtheria Toxin (DT) (Sigma, #D0564) was injected i.p. 4 times (d0, d1, d3 and d5) at a dose of 50 mg/kg of body weight.
To block emigration of lymphocytes from secondary lymphoid organs, FTY720 (ENZO Life Sciences), stock solution (10mg/mL in DMSO) was diluted to 25 mg/mL in PBS directly before administration and 5 mg were applied daily by oral gavage for the duration of the experiment. PBS containing DMSO was gavaged as control. To establish the FTY720 treatment regimen we determined the kinetics at which the inhibitor reduced the abundance of CD3 + cells in blood at treatment onset. These analyses showed that FTY720 reduced the abundance of CD3 + cells in blood by 69% within 3h, 86% within 6h and > 90% within 12h. Based on these data FTY720 was administered 3h prior to the initiation of the immunotherapies detailed in Figure 4 and Figure 5 .
Surface and intracellular staining and flow cytometry and cell sorting Surface staining was performed with mAbs for 30 min and with tetramers for 90 min at 4 C in PBS supplemented with 2% FCS and 0.01% azide (FACS buffer) using antibodies and Tetramers listed in STAR*Methods.
For intranuclear staining cells were first stained at the surface before fixation and permeabilization using the transcription factor staining kit (eBioscience) followed by intranuclear staining.
For the detection of cytokine production, splenocytes were re-stimulated in vitro with LCMV gp33-41 (gp33) peptide (1 mM) or Phorbol-12-myristat-13-acetat (PMA) (40ng/mL) plus Ionomycin (400ng/mL) for 4h in the presence of Brefeldin A (7 mg/mL). Cells were surface stained before fixation and permeablization (using kits from BD or eBioscience), which was followed by intracellular staining.
Cell surface stained cells were analyzed directly or washed twice and fixed in PBS supplemented with 1% formaldehyde, 2% glucose and 0.03% azide for 20 min at 4C. Then, cells were washed again and resuspended in FACS buffer.
For in vivo cell labeling, 2 mg of APC-Cy7 conjugated anti-CD8a Ab (clone 53-6.7) was injected i.v. into tumor bearing mice that had been adoptively transferred with P14 Tcf7 GFP cells and vaccinated one week prior to the analysis. Five minutes after i.v. Ab injection mice were sacrificed. Blood, spleen, dLN and tumors were isolated and single cell suspensions were used for flow cytometry. For apoptosis assays, TIL were cultured for 4 h or 12 h in the absence of growth factor addition before staining with Annexin V. 7-AAD was added just prior to data acquisition.
Flow cytometry measurements of cells were performed on an LSR-II or Fortessa flow cytometer (BD). Data were analyzed using FlowJo (TreeStar).
For cell sorting P14 T cells were enriched from TIL suspensions by staining with anti-CD8a (eBioscience, 53-6.7) and CD45.1 (A20) or CD45.2 (clone 104). Tcf7 GFP+ and Tcf7 GFP-CD8 + CD45.2 + cells were flow sorted on a FACSAria (BD) flow cytometer. The purity of sorted cells was greater than 99%.
Viral infection Flow sorted Tcf7
GFP+ and Tcf7 GFP-P14 TIL (CD45.2) (2x10 3 ) were transferred into naive B6 or Vb5 transgenic secondary recipients (CD45.1), which were infected i.p. with 2 3 10 5 plaque forming units (PFU) of LCMV 53b Armstrong (Arm).
Immunofluorescence labeling and microscopy B6 mice (CD45.1) were engrafted with naive P14 Tcf7 GFP reporter cells (CD45.2) and challenged with with B16-gp33 tumor cells one day later. Mice were left untreated or vaccinated with gp33 peptide plus poly(I:C) when tumors became palpable. Seven days later tumors were excised, fixed in 1% PFA in PBS, infiltrated with 30% sucrose overnight and then embedded and frozen in OCT compound. Frozen sections were labeled using the reagents listed STAR*Methods as described elsewhere (Schaeuble et al., 2017) . Images were acquired with a Zeiss AxioImager Z1 with a AxioCam MRC5 camera. Image analysis was done using Adobe Photoshop. For quantification of T cell localization relative to vessels images were exported to ImageJ (Fiji) and the scale was set based to one lymphocyte diameter. Distances between Tcf7 GFP+ and Tcf7 GFP-P14 cells to the nearest CD31 + structure were the manually determined and are indicated as cell diameters. 
RNA-seq analysis
Multiplex Immunohistochemistry and image acquisition
The histological analysis was performed on formalin-fixed paraffin-embedded (FFPE) primary melanoma or cutaneous melanoma metastases. Four mm thick sections of the FFPE tissue were used to perform an automated deparaffinization and multiplex staining using the Ventana Discovery Ultra automated slide stainer (Roche). After an initial deparaffinization procedure, a heat induced epitope retrieval (HIER) in EDTA buffer (pH8) at 95 C for 64 min was performed on all slides. Subsequently several rounds of staining consisting of antigen retrieval, blocking, primary antibody, HRP-coupled secondary antibody and tyramide signal amplification (TSA) steps were performed. Each round of staining was followed by an antibody stripping step (pH6, 100 C). To visualize immunofluorescent signaling the following OPAL TM (Perkin Elmer) TSA dyes were used: OPAL520, 570, 620, 650, 690. Spectral DAPI (Perkin Elmer) was used for the nuclear counterstain. Imaging of slides was performed on a Vectra 3.0 Automated Imaging System (Perkin Elmer). First, an overview of the whole tissue (10x magnification) was scanned. Then areas within the tumor and the tissue surrounding the tumor (tumor margin) were selected based on the Pan-Melanoma staining specific for HMB-45, MART-1 and Tyrosinase for higher-resolution imaging at 20x magnification using Phenochart (Perkin Elmer). The number of 20x images per sample scanned by the Vectra 3.0 microscope and used for further analysis is indicated in the Table with the patient characteristics
Image Analysis
High-resolution images of intratumoral and marginal tumor regions were analyzed by the inForm2.3.0 Software. Tumor and stroma regions were distinguished based on pattern recognition of Pan-Melanoma positive (tumor) and negative (stroma) areas. Cell segmentation was performed based on nuclear DAPI counterstain. Subsequently, for each phenotype 10-15 representative cells were identified manually in order to train a phenotyping algorithm for automated analysis. Batch analysis was performed on all high-resolution images using an algorithm that was generated based on 4-5 representative images per patient sample. Algorithms were generated for individual patient samples (6 out of 13 patients) or for pools of 3-4 patient samples (each time containing both responder and non-responder samples. Images showing poor tissue quality as well as cells with a phenotype confidence below 40% were excluded from the analysis. The experimenter was not blinded to the type of samples. Multiplex analysis: Melanoma patients, clinical characteristics and tissues analyzed
Analysis of single cell RNaseq data Processed single-cell gene expression data from human melanoma samples (see patient characteristics below) (Tirosh et al., 2016) were downloaded from Gene Expression Omnibus (GEO: GSE72056). Gene expression levels (E) in these data consist of log2 (TPM/ 10 + 1), where TPM refers to transcripts per million as estimated by RSEM (Li and Dewey, 2011) . The analysis was restricted to CD8 + T cells that were identified based on the expression of CD2, CD3E, CD3D, CD3G, CD8A and CD8B (E > 1) but not CD4 (E = 0). CD8 + T cells were classified based on TCF7 (TCF1) and PDCD1 (PD-1) expression as TCF7 + PDCD1 + (if E > 1 for both), TCF7 -PDCD1 + (if E(PDCD1)>1 and E(TCF7)<1) and TCF7 + PDCD1 -(if E(PD-1)<1 and E(TCF7)>1). The heatmaps that show the expression of the indicated marker genes among PDCD1 + CD8 + TIL were generated using pheatmap R package. PDCD1 + cells (E(PDCD1) > 1) were grouped by hierarchical clustering using euclidean distance and average-linkage, considering all displayed marker genes, except for CD2, CD3 and CD8 (that were pre-selected).
The fraction of cells expressing both TCF7 and PDCD1 (E > 1) over the total number of CD8 + TILs was compared between patients that received Nivolumab (Nivo) treatment (n = 3) and those that did not (either untreated or different treatment, n = 8) (see Table below ).
Melanoma patients for single cell RNA seq analysis (Tirosh et al., 2016) Survival Analysis of TCGA data TCGA normalized RNA-seq data from 103 primary melanoma tumors were downloaded using TCGAbiolinks R package (v2.6.12) on January 2018. Kaplan-Meier survival curves were generated using Survival and TCGAbiolinks R Packages. Differences between survival curves were evaluated using Log-rank test, where samples/patients were split based on normalized gene expression levels into lower (50%) and higher (50%) values. T cell infiltration (and therefore, also T cell genes such as CD2 and CD3) was correlated with survival (not shown). To assess differences in survival associated with specific T cell populations (e.g., TCF7
+ PDCD1 + CD8 + T cells),
we focused on patients with a high T cell signature score. To this end, we calculated a T cell signature score as the average (arithmetic mean) of the normalized log2 expression values of CD8A, CD8B, CD2, CD3G, CD3E and CD3D. Next, samples were segmented into the 50% with lower and the 50% with higher T cell signature score. Within the high T cell score group, expression of the T cell signature (or of any individual gene in the signature) was no longer associated with improved survival (effectively controlling for T cell infiltration benefit, see Figure S9J ). However, the combined expression of TCF7 and PDCD1 (average of their normalized values) showed a significant association with survival.
QUANTIFICATION AND STATISTICAL ANALYSIS
Bar graphs depict means ± SEM or ± SD as indicated in the corresponding legends. Statistical analyses were performed using Prism 6.0 and 7.0 (Graphpad Software). Non-paired t test (two-tailed) was used for the comparison of 2 datasets. Anova was used for > 2 comparison groups. p values < 0.05 were considered significant (*: p < 0.05; **: p < 0.01; ***: p < 0.001); p-values > 0.05; non-significant (ns).
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